Member Info for D-Geeman

I am expecting news early next week (with Labor Day yesterday).

'Have any PIs actually bought into the current offer? '

I have indicated that I will. I rather hope the sp stays stable for the moment. If it were to rise now then the offer will get over-subscribed and scaled back accordingly.

If it's 'working days' then I think we can add on 25 days (12 weekends and July 4th) so around September 8th / 9th.

This seems to be the nomination stage, not voting yet.

'Nominations for Fiercest Women in Life Sciences 2024

**As a reminder, please avoid organizing efforts to stuff the entry form with

repeat nominations for the same person! One detailed nomination is more than enough

for our deliberations.**

Hard to imagine they'd reveal the new CEO (' transforming the IP into transformative business development deals and M&A transactions') and then almost immediately announce they'd failed with the Orphan status application.

Not the news I was expecting today.

'NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately.

"We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building intellectual property portfolios and transforming the IP into transformative business development deals and M&A transactions. Tiziana looks forward to creating further value with Ivor as we proceed with our human clinical trials."

https://www.premieriplawyers.com/expert-directory/ivor-elrifi/

Dr. Ivor Elrifi is the chair of Cooley’s patent counseling and prosecution practice group. He advises pharmaceutical, biotechnology, life sciences and medical device companies, research institutions, universities, hospitals and governments throughout the world, particularly in the US and Europe. His practice includes patent prosecution, litigation, arbitration, licensing and transactional work with a focus on novel therapeutic treatments, biotechnology, genetics, diagnostics, biomarkers, drug formulations and medical devices.

Ivor counsels clients worldwide in developing and implementing patent strategies and in the prosecution, licensing and enforcement of patents. He has extensive experience in advising clients on transactional work and regularly counsels clients with respect to investments, mergers and acquisitions. He has also advised plaintiffs and defendants in patent litigation and arbitration cases.

Ivor is widely recognized as one of the top life sciences patent lawyers in the world by numerous prominent legal directories and publications. In 2018, he was singled out as the “Patent Strategy & Management Attorney of the Year” by LMG Life Sciences (he also won the award in 2016). In addition, year after year, including 2018, he has been named a “Life Sciences Star” by LMG Life Sciences, an “IP Star” by Managing Intellectual Property, a leading patent lawyer by IAM Patent 1000, recognized as one of the world’s leading

experts on patent law by Euromoney, and named a leader in IP law by Chambers, Legal 500 and Super Lawyers.

Prior to joining Cooley, Ivor was co-chair and section manager of Mintz Levin’s intellectual property practice and a member of the firm’s management committee. Earlier in his career, he served as patent counsel and then general counsel and vice president for CytoTherapeutics in Providence, Rhode Island, and as patent counsel to Modex Therapeutics in Lausanne, Switzerlan

'Middle of august is always good time to buy ! '

Is It really?

15/8/23. AVCT SP at Open 104p. So roughly 35p higher than today.

15/8/22. SP at Open 111p. So roughly 44p higher than today.

17/8/21. SP at Open 105p. So roughly 36p higher than today.

17/8/20. SP at Open 144p. So roughly 76p higher than today.

Yes, if you bought in August 2019 you'd be right, but that's not what you meant is it watching2? Had you heard of AVCT in 2019

The casual visitor to this bb might actually thing Watching2 knows what he is talking about.

This is a few years old:

https://www.fda.gov/media/106012/download

And seems "no ifs, no buts" 'the agency is committing to respond to 100 percent of all new orphan drug designation requests within 90 days of their receipt by FDA.'

So if it was a straight 'no' surely they'd have come out and said so. IMHO should be news after market close today, or some time tomorrow. (Famous last words.)

'Who is betting this falls through $1 today?'

You, by the sounds of it!

If you think the Orphan news is bad, you know what to do. Conversely I'm sure people expecting good news will be poised to buy.

'NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a .......

....... today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.'

So whatever the Orphan news, they get to stay on the Nas. One assumes they hope for positive Orphan news but if they worked things so that, even in the worst scenario, they stay on the Nas, that would be an advantage. I take it that Orphan news will now be very very close.

Don't they tend to release news after the market closes in Wall Street. But friday would be seen as poor timing for an RNS here. Does anyone know the form there.

I made a mistake using alexa to tell me how many working days there are from May 13 (Orphan application day).

It's actually mid September, September 16th though I only included 4th july holiday.

Or is it simply 90 calendar days and hence the rise today..

‘ if he gets in ’ 😱😱😱

Watching2 heard that if he buys a single share it guarantees an RNS.

Just to make extra sure, he bought 2. As we all know that's now spoiled the magic..

' If Avacta was an oil exploration stock' comment reminds me...

'At a recent computer exposition, Bill Gates reportedly compared the computer industry with the auto industry and stated: “If General Motors had kept up with the technology like the computer industry has, we would all be driving $25.00 cars that got 1,000 miles to the gallon.”

In response to Bill’s comments, GM issued a press release stating: “If General Motors had developed technology like Microsoft, we would all be driving cars with the following characteristics:

For no reason whatsoever, your car would crash twice a day.

Every time they repainted the lines in the road, you would have to buy a new car.

Occasionally your car would die on the freeway for no reason. You would have to pull over to the side of the road, close all of the windows, shut off the car, restart it, and reopen the windows before you could continue. For some reason, you would simply accept this.

Occasionally, executing a maneuver such as a left turn would cause your car to shut down and refuse to restart, in which case you would have to reinstall the engine.

Macintosh would make a car that was powered by the sun, was reliable, five times as fast and twice as easy to drive – but would run on only five percent of the roads.

The oil, water temperature, and alternator warning lights would all be replaced by a single “General Protection Fault” warning light.

The airbag system would ask “Are you sure?” before deploying.

Occasionally, for no reason whatsoever, your car would lock you out and refuse to let you in until you simultaneously lifted the door handle, turned the key and grabbed hold of the radio antenna.

Every time GM introduced a new car, car buyers would have to learn to drive all over again because none of the controls would operate in the same manner as the old car.

You’d have to press the “Start” button to turn the engine off.'

'They'll take all mine for above the bid plus 100%'

Careful not to mix up the 'confirm' and the 'cancel' buttons on those dummy sells..

I prefer to let them time out, not that I do it often.

'intranasal FDA orphan drug application filed on 13 may. We should hear within next 28 days (if within 90 day schedule is upheld'

'FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis 11th June 2024’

So that should mean that news on both would arrive by August 9th or 10th..

Morning Wyn, morning Pedro and Safebreaker.

Pedro: 'No-one is interested in your constant attempts to knock the company '. Well I find Wyn's comments useful (and I wouldn't characterise them as simply 'knocking' the company actually) and I see 6 others have given Recs so I would say you are mistaken on the 'no-one'.

And as if to prove the point take a look at Safebreakers own history and you'll see even he's unable to stick to his own commitment to green-bin Wyn. Even though he's far from being a wyn fan, he's removed wyn from the bin on at least 2 occasions so there must be something of interest in his posts, even to safebreaker.

Safebreaker

Posted in: AVCT

Posts: 151

Price: 106.50

No Opinion

RE: Formality13 Aug 2023 15:45

WYN, you are wind up merchant. I have just taken you out of the bin and there you are spouting the usual crap with little research. In the bin!

Bella,

I thought they’d never test anti cancer drugs on healthy people but this is interesting:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469970/#:~:text=Though%20inclusion%20of%20healthy%20volunteers,dose%20pharmacokinetics%20in%20cancer%20patients.

She's used up £18,249 of her ISA allowance for 24/25.

If she thought HE1 is a dud then why would she do that.